{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:25:50Z","timestamp":1762543550188,"version":"3.44.0"},"reference-count":20,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/bmj.com\/coronavirus\/usage"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,11,18]]},"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:p>We describe a patient who developed bilateral oculomotor nerve palsy, ataxia, facial diplegia and lower limb weakness 2\u2009weeks post-Oxford-AstraZeneca SARS-CoV2 vaccination, consistent with Miller-Fisher syndrome (MFS) and Guillain-Barre syndrome (GBS) overlap syndrome. Although some features of the patient\u2019s presentation were typical of recently reported cases of a rare GBS variant post-Oxford-AstraZeneca vaccination, including severe facial weakness and a lack of respiratory involvement, to our knowledge this is the first reported case of MFS associated with SARS-CoV2 vaccination. While postvaccination GBS remains rare, it appears to have a favourable prognosis, and recognising this entity is therefore important for patient counselling and monitoring for potential complications.<\/jats:p>","DOI":"10.1136\/bcr-2021-246701","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T12:13:00Z","timestamp":1638274380000},"page":"e246701","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Miller-Fisher Syndrome and Guillain-Barre Syndrome overlap syndrome in a patient post Oxford-AstraZeneca SARS-CoV-2 vaccination"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0570-5398","authenticated-orcid":false,"given":"Yew Li","family":"Dang","sequence":"first","affiliation":[{"name":"Department of Neurology, Box Hill Hospital, Box Hill, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0033-8197","authenticated-orcid":false,"given":"Alexander","family":"Bryson","sequence":"additional","affiliation":[{"name":"Department of Neurology, Austin Health, Heidelberg, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"2025082710595429000_14.11.e246701.1","doi-asserted-by":"publisher","DOI":"10.1159\/000324710"},{"key":"2025082710595429000_14.11.e246701.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00339-1"},{"key":"2025082710595429000_14.11.e246701.3","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain\u2013Barr\u00e9 syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025082710595429000_14.11.e246701.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.003"},{"key":"2025082710595429000_14.11.e246701.5","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/pds.3638","article-title":"Risk of Guillain-Barr\u00e9 syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany","volume":"23","author":"Prestel","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025082710595429000_14.11.e246701.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62189-8"},{"key":"2025082710595429000_14.11.e246701.7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.26144","article-title":"Guillain-Barr\u00e9 syndrome variant occurring after SARS-CoV-2 vaccination","volume":"90","author":"Allen","year":"2021","journal-title":"Ann Neurol"},{"key":"2025082710595429000_14.11.e246701.8","article-title":"Bilateral facial weakness with paraesthesia variant of Guillain-Barr\u00e9 syndrome following Vaxzevria COVID-19 vaccine","author":"Bonifacio","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025082710595429000_14.11.e246701.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70130-8"},{"key":"2025082710595429000_14.11.e246701.10","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410440512"},{"key":"2025082710595429000_14.11.e246701.11","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1016\/j.vaccine.2012.03.013","article-title":"Atypical forms of Guillain-Barr\u00e9 syndrome and H1N1-influenza vaccination","volume":"30","author":"Shaikh","year":"2012","journal-title":"Vaccine"},{"key":"2025082710595429000_14.11.e246701.12","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1111\/ene.14473","article-title":"Miller-Fisher syndrome after COVID-19: neurochemical markers as an early sign of nervous system involvement","volume":"27","author":"Senel","year":"2020","journal-title":"Eur J Neurol"},{"key":"2025082710595429000_14.11.e246701.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2003.11.017"},{"key":"2025082710595429000_14.11.e246701.14","article-title":"Miller fisher syndrome in the COVID-19 Era - a novel target antigen calls for novel treatment","volume":"13","author":"Kajani","year":"2021","journal-title":"Cureus"},{"key":"2025082710595429000_14.11.e246701.15","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.4103\/0028-3886.266262","article-title":"Miller Fisher syndrome following tetanus, diphtheria, and pertussis (Tdap) vaccine","volume":"67","author":"Garg","year":"2019","journal-title":"Neurol India"},{"key":"2025082710595429000_14.11.e246701.16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jinf.2012.11.014","article-title":"Postvaccination Miller Fisher syndrome after combined pertussis, diphtheria and tetanus toxoid vaccine","volume":"66","author":"Kr\u00e4mer","year":"2013","journal-title":"J Infect"},{"key":"2025082710595429000_14.11.e246701.17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s15010-011-0184-7","article-title":"Miller-Fisher syndrome following vaccination against influenza virus A\/H1N1 in an AIDS patient","volume":"40","author":"Annunziata","year":"2012","journal-title":"Infection"},{"key":"2025082710595429000_14.11.e246701.18","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.236"},{"key":"2025082710595429000_14.11.e246701.19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4321\/S0365-66912008000700008","article-title":"S\u00edndrome de Miller Fisher, oftalmoplej\u00eda interna Y externa tras vacunaci\u00f3n antigripal","volume":"83","author":"Blanco-Marchite","year":"2008","journal-title":"Arch Soc Esp Oftalmol"},{"key":"2025082710595429000_14.11.e246701.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2008.01.013"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-246701","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T18:00:06Z","timestamp":1756317606000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-246701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,30]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1136\/bcr-2021-246701"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-246701","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}